Mobile

An open label phase II study to find out if the drug PDR001 is safe and has beneficial effects in patient who have advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointe...

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-002522-36

An open label phase II study to find out if the drug PDR001 is safe and has beneficial effects in patient who have advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal, or thoracic origins and have progressed on prior treatment

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To estimate the antitumor activity of PDR001 as a single agent in patients with non-functional NET

Critère d'inclusion

  • Advanced neuroendocrine tumor (NET) of pancreatic, GI or lung origin

Liens